ANGPT2 and hepatocellular carcinoma: From the clinical point of view, our model for the prediction of HCC recurrence after LT based on angiopoietin-2 would be a useful tool to identify the best candidates for LT, optimize the radiological schedule of follow-up, and finally determine the optimal target population that could receive maximal benefit from novel adjuvant treatments blocking the angiopoietin-2 pathway.